Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Leap Therapeutics Inc LPTX

Healthcare Biotechnology

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic... see more

Add To Watchlist

Recent & Breaking News (NDAQ:LPTX)

Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results

PR Newswire November 9, 2018

Leap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting

PR Newswire November 9, 2018

Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress

PR Newswire October 21, 2018

Leap Therapeutics to Present Data from Study Evaluating DKN-01 in Combination with KEYTRUDA® (pembrolizumab) at the European Society of Medical Oncology 2018 Congress

PR Newswire October 8, 2018

Leap Therapeutics to Present at Two October Conferences

PR Newswire September 25, 2018

Leap Therapeutics to Participate in the H.C. Wainwright 20th Annual Global Investment Conference

PR Newswire August 30, 2018

Recent Analysis Shows Leap Therapeutics, Gardner Denver, Medical Transcription Billing, CarGurus, Liberty Media, and Quorum Health Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire August 22, 2018

Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results

GlobeNewswire August 8, 2018

Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors

GlobeNewswire July 23, 2018

Analysis: Positioning to Benefit within Ruth's Hospitality Group, S&P Global, Shaw Communications, Leap Therapeutics, Red Hat, and Welltower — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire June 13, 2018

Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference

GlobeNewswire June 13, 2018

Leap Therapeutics Reports First Quarter 2018 Financial Results

GlobeNewswire May 11, 2018

Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting

GlobeNewswire April 16, 2018

New Research Coverage Highlights Holly Energy Partners, Liberty Property Trust, Fair Isaac, 58, Cousins Properties, and Leap Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire March 28, 2018

Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire March 27, 2018

Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock

GlobeNewswire March 23, 2018

A Peek Into The Markets: U.S. Stock Futures Signal Lower Start On Wall Street

Benzinga.com March 23, 2018

8 Stocks To Watch For March 23, 2018

Benzinga.com March 23, 2018

Leap Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire March 22, 2018

Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference

GlobeNewswire March 21, 2018